These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 25787234)

  • 1. Tofacitinib, a novel JAK3 inhibitor, as a potential cause of distal symmetric polyneuropathy.
    Zeidler C; von Köckritz A; Luger TA; Ständer S; Husstedt IW; Tsianakas A
    J Eur Acad Dermatol Venereol; 2016 Jun; 30(6):1066-7. PubMed ID: 25787234
    [No Abstract]   [Full Text] [Related]  

  • 2. XELJANZ (Tofacitinib) for Chronic Plaque Psoriasis.
    Gupta AK; Daigle D; Abramovits W; Vincent KD
    Skinmed; 2015; 13(3):227-9. PubMed ID: 26380510
    [No Abstract]   [Full Text] [Related]  

  • 3. Tofacitinib for the treatment of moderate-to-severe psoriasis.
    Chiricozzi A; Faleri S; Saraceno R; Bianchi L; Buonomo O; Chimenti S; Chimenti MS
    Expert Rev Clin Immunol; 2015 Apr; 11(4):443-55. PubMed ID: 25666451
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tofacitinib (CP-690,550), an oral Janus kinase inhibitor, improves patient-reported outcomes in a phase 2b, randomized, double-blind, placebo-controlled study in patients with moderate-to-severe psoriasis.
    Mamolo C; Harness J; Tan H; Menter A
    J Eur Acad Dermatol Venereol; 2014 Feb; 28(2):192-203. PubMed ID: 23294276
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tofacitinib and other kinase inhibitors in the treatment of psoriasis.
    Ortiz-Ibáñez K; Alsina MM; Muñoz-Santos C
    Actas Dermosifiliogr; 2013 May; 104(4):304-10. PubMed ID: 23583515
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tofacitinib for the treatment of recalcitrant palmoplantar pustulosis: A case report.
    Haynes D; Topham C; Hagstrom E; Greiling T
    Australas J Dermatol; 2020 Feb; 61(1):e108-e110. PubMed ID: 31318041
    [No Abstract]   [Full Text] [Related]  

  • 7. Tofacitinib versus etanercept or placebo in moderate-to-severe chronic plaque psoriasis: a phase 3 randomised non-inferiority trial.
    Bachelez H; van de Kerkhof PC; Strohal R; Kubanov A; Valenzuela F; Lee JH; Yakusevich V; Chimenti S; Papacharalambous J; Proulx J; Gupta P; Tan H; Tawadrous M; Valdez H; Wolk R;
    Lancet; 2015 Aug; 386(9993):552-61. PubMed ID: 26051365
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy of tofacitinib, an oral janus kinase inhibitor, on clinical signs of moderate-to-severe plaque psoriasis in different body regions.
    Menter A; Papp KA; Tan H; Tyring S; Wolk R; Buonanno M
    J Drugs Dermatol; 2014 Mar; 13(3):252-6. PubMed ID: 24595567
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of tofacitinib on lymphocyte sub-populations, CMV and EBV viral load in patients with plaque psoriasis.
    Valenzuela F; Papp KA; Pariser D; Tyring SK; Wolk R; Buonanno M; Wang J; Tan H; Valdez H
    BMC Dermatol; 2015 May; 15():8. PubMed ID: 25951857
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Killing two birds with one stone: oral tofacitinib reverses alopecia universalis in a patient with plaque psoriasis.
    Craiglow BG; King BA
    J Invest Dermatol; 2014 Dec; 134(12):2988-2990. PubMed ID: 24940651
    [No Abstract]   [Full Text] [Related]  

  • 11. Emerging Oral Immunomodulators for the Treatment of Psoriasis: A Review of Phase III Clinical Trials for Apremilast and Tofacitinib.
    McAndrew R; Levin E; Koo J
    J Drugs Dermatol; 2015 Aug; 14(8):786-92. PubMed ID: 26267722
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tofacitinib for the treatment of psoriasis.
    Galluzzo M; D'Adamio S; Servoli S; Bianchi L; Chimenti S; Talamonti M
    Expert Opin Pharmacother; 2016 Jul; 17(10):1421-33. PubMed ID: 27267933
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tofacitinib versus etanercept or placebo in patients with moderate to severe chronic plaque psoriasis: patient-reported outcomes from a Phase 3 study.
    Valenzuela F; Paul C; Mallbris L; Tan H; Papacharalambous J; Valdez H; Mamolo C
    J Eur Acad Dermatol Venereol; 2016 Oct; 30(10):1753-1759. PubMed ID: 27271195
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Randomized Pilot Clinical Trial of Tofacitinib Solution for Plaque Psoriasis: Challenges of the Intra-Subject Study Design.
    Ports WC; Feldman SR; Gupta P; Tan H; Johnson TR; Bissonnette R
    J Drugs Dermatol; 2015 Aug; 14(8):777-84. PubMed ID: 26267721
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Profile of tofacitinib citrate and its potential in the treatment of moderate-to-severe chronic plaque psoriasis.
    Di Lernia V; Bardazzi F
    Drug Des Devel Ther; 2016; 10():533-9. PubMed ID: 26889081
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Reduction of Inflammatory and Cardiovascular Proteins in the Blood of Patients with Psoriasis: Differential Responses between Tofacitinib and Etanercept after 4 Weeks of Treatment.
    Kim J; Tomalin L; Lee J; Fitz LJ; Berstein G; Correa-da Rosa J; Garcet S; Lowes MA; Valdez H; Wolk R; Suarez-Farinas M; Krueger JG
    J Invest Dermatol; 2018 Feb; 138(2):273-281. PubMed ID: 28927890
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Alopecia universalis unresponsive to treatment with tofacinitib: report of a case with a brief review of the literature.
    Salman A; Sarac G; Ergun T
    Dermatol Online J; 2017 Jul; 23(7):. PubMed ID: 29469706
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Validation of the Itch Severity Item as a Measurement Tool for Pruritus in Patients with Psoriasis: Results from a Phase 3 Tofacitinib Program.
    Ständer S; Luger T; Cappelleri JC; Bushmakin AG; Mamolo C; Zielinski MA; Tallman AM; Yosipovitch G
    Acta Derm Venereol; 2018 Mar; 98(3):340-345. PubMed ID: 29182790
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Early clinical response to tofacitinib treatment as a predictor of subsequent efficacy: Results from two phase 3 studies of patients with moderate-to-severe plaque psoriasis.
    Tan H; Valdez H; Griffins CE; Mrowietz U; Tallman A; Wolk R; Gordon K
    J Dermatolog Treat; 2017 Feb; 28(1):3-7. PubMed ID: 27538247
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Application of the Itch Severity Score in patients with moderate-to-severe plaque psoriasis: Clinically important difference and responder analyses.
    Mamolo CM; Bushmakin AG; Cappelleri JC
    J Dermatolog Treat; 2015 Apr; 26(2):121-3. PubMed ID: 24716586
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.